Isomorphic Labs, the AI drug discovery platform spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round to move new drug candidates into clinical trials.
The funding was co-led by Greenoaks and Sequoia Capital, with participation from new investor Andreessen Horowitz and other investors. The company’s existing backers, including Alphabet’s venture arm GV and Capita G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund, all also invested.
Isomorphic Labs is building an AI drug design engine that uses numerous simulation AI models that explore various areas of chemistry to aid the company’s drug design. The company, whose research is based on DeepMind’s breakthrough AlphaFold protein folding AI model, said its program has produced “positive preclinical results” in oncology and immunology. The institute has contracts with major pharmaceutical companies including Eli Lilly, Novartis, and Johnson & Johnson.
The new funding, which follows a $2.1 billion Series B round in May, will be used to continue developing the drug design engine and expand into more types of drugs.
The Series C is Isomorphic’s first funding since Demis Hassabis, Isomorphic’s founder and CEO, stepped down as DeepMind’s executive director to focus on drug discovery and became DeepMind’s chairman. Hassabis and John Jumper, then head of DeepMind, won the Nobel Prize in Chemistry for their lab’s work on alphafold, a system that predicts the three-dimensional structure of proteins based solely on gene sequence.
Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the institute was considering raising capital at a valuation of $50 billion.
